High serum levels of CXCL13 predict lower response to csDMARDs in both ACPA-positive and ACPA-negative early rheumatoid arthritis
High serum levels of CXCL13 identify a subgroup of RA patients who are more refractory to first-line treatment with MTX. CXCL13 appears a promising biomarker of response to MTX in both ACPA-positive and -negative early RA.
Authors
- Emanuele Bozzalla Cassione (ORCID: https://orcid.org/0000-0001-6578-6938)
- Carlomaurizio Montecucco (ORCID: https://orcid.org/0000-0001-8263-3925)
- Ludovico De Stefano (ORCID: https://orcid.org/0000-0002-2312-2161)
- Antonio Manzo (ORCID: https://orcid.org/0000-0002-9743-6008)
- Terenzj Luvaro (ORCID: https://orcid.org/0000-0003-3187-3843)
- Serena Bugatti (ORCID: https://orcid.org/0000-0002-5396-7077)
- Ylenia Sammali
Institutions
- University of Pavia (IT)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1093/rheumatology/keae596
- Citations
- 3
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- Fondazione IRCCS Policlinico San Matteo